The Food and Drug Administration yesterday approved the first continuous glucose monitoring system with a fully implantable sensor, designed to measure glucose levels in adults with diabetes for up to 90 days. Once implanted under the skin during an outpatient procedure, the sensor sends information to a mobile app to alert users if glucose levels are too high or too low. “The FDA is committed to advancing novel products that leverage digital technology to improve patient care,” said FDA Commissioner Scott Gottlieb, M.D.

Related News Articles

Headline
The Federal Communications Commission today released a final rule summarizing guidance adopted last month for participants in its $100 million Connected…
Headline
The AHA today expressed support for the Protecting Rural Telehealth Access Act (S. 1988), legislation that would make permanent several telehealth…
#HealthCareInnovation Thursday Blog
The past year of the COVID-19 pandemic has transformed digital health into a necessity. We are more reliant than ever on technology to access health care…
Headline
Eligible states and tribal organizations can apply through July 6 for up to $445,000 each from the American Rescue Plan Act to implement telehealth networks to…
Perspective
As our country continues to emerge slowly from the COVID-19 pandemic, the value of America’s hospitals and health systems – and the 6 million women and men who…
Blog
The Centers for Medicare & Medicaid Services recently announced that Medicare will not continue to cover audio-only telehealth visits when the COVID-19…